Open company graph database — free web & API
Login

Daipon Pharmaceutical Industries Co., Ltd.

大鵬薬品工業株式会社
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
2,149
Related companies
11
§01

Basic information

BASIC
Head office
1-27 Kanda Nishikicho, Chiyoda-ku, Tokyo 101-8444
Chief executive
Shou-ichi Kobayashi
Capital
200,000,000 JPY (2 100 millionJPY)
Employees (non-consolidated)
2,149 people
Employees (consolidated)
2,149 people
Start date
1963-06-01
End date
§02

Websites

1 DOMAINS
§03

Business

5
Manufacturing and sale of pharmaceuticalsManufacturing and sale of quasi-drugsManufacturing and sale of medical devicesManufacturing and sale of food productsManufacturing and sale of daily household goods
§04

Related companies

11 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Da Peng Pharmaceutical Information Consulting (Beijing) Co., Ltd.
Group
Taiho Innovations Inc.
Group
EN Otsuka Pharmaceutical Co., Ltd.
Group
Otsuka Holdings Co., Ltd.
Group
Otsuka Medical Devices Co., Ltd.
Group
Otsuka Pharmaceutical Factory, Inc.
Group
Otsuka Foods Co., Ltd.
Group
Otsuka Chemical Co., Ltd.
Group
Otsuka Warehouse Co., Ltd.
Group
Ariruju Co., Ltd.
Group
Okayama Daipō Pharmaceutical Co., Ltd.
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

55 EVENTS

Daipon Pharmaceutical Industries Co., Ltd. was established with a capital of 25 million yen.Sources

Naruto Factory in Tokushima Prefecture was completed.Sources

"Chiovita Drink" was launched.Sources

Sales outlets were opened at nine locations nationwide.Sources

Capital was increased to 200 million yen.Sources

A contract was signed with the Soviet Union Pharmaceutical Import-Export Agency for the introduction of "Futuraul."Sources

Tokushima Factory (freeze-drying formulation plant) in Tokushima Prefecture was completed.Sources

A strategic alliance and capital participation were established with Nichiban Co., Ltd.Sources

Completion of the welfare facility "Otsuka Tengiyama Villa"Sources

A business alliance and capital participation were established with Antibody Chemical Industry. A GMP-compliant injection drug plant was completed in the Tokushima Factory, and plant consolidation was finished.Sources

"Solmac" was launched.Sources

A GLP-compliant development and safety research institute was completed in the Tokushima Factory.Sources

The headquarters factory of Antibody Chemical Industry Co., Ltd. (100% owned) was completed in Saitama Prefecture, and the Kodama Research Institute was opened.Sources

The headquarters was relocated to 1-27 Kanda Nishikicho, Chiyoda-ku, Tokyo.Sources

Symphar Research Institute was opened in Alberta, Canada.Sources

A formulation research institute was opened in the Tokushima Factory.Sources

Completion of the Drug Discovery Center, Training Center, and Computing Center in Saitama PrefectureSources

Acquisition of shares in Shinzen Pharmaceutical Co., Ltd. and capital participationSources

Completion of the Okayama Factory in Okayama PrefectureSources

Renamed Shinzen Pharmaceutical to Okayama Daipō Pharmaceutical Co., Ltd. and Antibody Production Industry to Daipō Fine Chemical Co., Ltd.Sources

Absorbed Daipō Fine Chemical and commenced operations as the Saitama FactorySources

Completion of a GMP-compliant clinical trial drug manufacturing plant at the Tokushima FactorySources

Established a U.S. office in New York StateSources

Kobayashi Yukio appointed Chairman of the BoardSources

Usami Michi appointed PresidentSources

Established TAIHO PHARMA U.S.A., INC. (now TAIHO ONCOLOGY, INC.) in New Jersey, USASources

Inuyama Factory (Aichi Prefecture) Commencement of OperationsSources

Signed a license agreement with Helsinn Healthcare S.A. for the new antiemetic "Aroxi"Sources

Signed a license agreement with American BioScience, Inc. (at the time of the contract) for the anticancer drug "Abracasan"Sources

Completion of Headquarters AnnexSources

Completion of a new solid drug plant at the Tokushima FactorySources

Established Otsuka Holdings Co., Ltd.Sources

Established Daipō Pharmaceutical Information Consulting (Beijing) Co., Ltd. in Beijing, ChinaSources

Acquired the Tsukuba Research Institute of Manju Pharmaceutical in Ibaraki PrefectureSources

Established TAIHO PHARMA SINGAPORE PTE. LTD. (now TAIHO PHARMA ASIA PACIFIC PTE. LTD.) in SingaporeSources

Kobayashi Masayuki appointed PresidentSources

Signed a license agreement with Faes Farma, S.A. for the antiallergy drug "Bilanova"Sources

Completion of the Kitajima Factory in Tokushima PrefectureSources

Entered into an asset transfer agreement concerning assets related to fermentation drug development with Astellas Pharma Inc.Sources

Entered into a co‑sales agreement with Meiji Seika Pharma Co., Ltd. for "Bilanova".Sources

Established TAIHO VENTURES, LLC in California, USA.Sources

Completed the CTM building (clinical trial drug manufacturing facility) within Kitajima Factory.Sources

Established TAIHO PHARMA CANADA, INC. in Ontario, Canada.Sources

Entered into an option agreement with Arcus Biosciences, Inc.Sources

Entered into a co‑promotion agreement in Japan for the human anti‑interleukin‑23 (IL‑23) monoclonal antibody product "Tremfeya" with Janssen Pharma Co., Ltd.Sources

Completed the HP building (high‑potency API manufacturing facility) within the Saitama Factory.Sources

Established Taiho Innovations LLC in Tokyo, Japan.Sources

Transferred the North American sales rights for INQOVI from Otsuka Pharmaceutical Co., Ltd.Sources

Entered into a license agreement with Cullinan Pearl Corp., operated by Cullinan Oncology, Inc. (at the time of the agreement) in the United States.Sources

Entered into a strategic partnership agreement in the oncology field with Taiho Pharmaceutical, Astex Pharmaceuticals, Inc., and Merck & Co., Inc., Kenilworth, N.J., U.S.A.Sources

Established Taiho Oncology Europe GmbH in Zug, Switzerland.Sources

Completed the new headquarters building.Sources

Entered into a co‑development and co‑sales agreement with Cullinan Oncology for CLN‑081/TAS6417 and a contract related to the acquisition of Cullinan Pearl Corp. by Taiho Pharmaceutical.Sources

Established Arilju Co., Ltd. in Tokyo, Japan.Sources

Made Araris Biotech AG, which has a next‑generation ADC drug‑development technology platform, a subsidiary.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information1010001021927
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
大鵬薬品工業株式会社
Trade name (kana)
タイホウヤクヒンコウギョウ
Name in English
Corporation type
301
Address
〒101-0054 東京都千代田区神田錦町1丁目27番地
Postal code
1010054
Prefecture code
13
City code
101
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-05-09
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
00049186
Address image ID
Sequence number
1270957
METI gBizINFO1010001021927
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
1010001021927
Trade name
大鵬薬品工業株式会社
Trade name (kana)
タイホウヤクヒンコウギョウ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都千代田区神田錦町1丁目27番地
Postal code
1010054
Prefecture
東京都
Prefecture code
13
City or district
千代田区
City code
101
Street address
神田錦町1丁目27番地
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
Capital
Employees
2399
Employees (male)
1755
Employees (female)
630
Business summary
医薬品、医薬部外品、医療機器などの製造及び販売輸出入
Website URL
https://www.taiho.co.jp/csr/diverse/
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-05-09
Key information
1010001021927
§09

Sources & updates

SOURCES
↑